Upstream Bio (UPB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Apr, 2026Voting matters and shareholder proposals
Election of two class II directors to serve until the 2029 annual meeting, with nominees H. Edward Fleming, Jr., M.D. and Liam Ratcliffe, M.B.Ch.B., Ph.D.
Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Proxies authorized to vote on other business that may arise during the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of both director nominees and the auditor ratification.
Directors elected will serve three-year terms, expiring at the 2029 annual meeting.
Audit committee and external auditor matters
Proposal to ratify PricewaterhouseCoopers LLP as the external auditor for the 2026 fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Upstream Bio
- Verekitug cut severe asthma exacerbations by 56% and improved lung function with strong safety.UPB
Study result20 Apr 2026 - Virtual meeting to elect directors, ratify auditor, and reinforce governance and oversight.UPB
Proxy filing16 Apr 2026 - Verekitug demonstrated strong efficacy and safety in Phase 2, with Phase 3 trials set for 2027.UPB
Corporate presentation8 Apr 2026 - Verekitug demonstrated strong efficacy and safety in Phase 2, with Phase 3 trials set for 2027.UPB
Corporate presentation26 Mar 2026 - Strong Phase 2 results and robust cash position support a high-dose quarterly Phase 3 strategy.UPB
Q4 202526 Mar 2026 - Phase II data support quarterly dosing for verekitug, with phase III and COPD programs advancing.UPB
Leerink Global Healthcare Conference 20269 Mar 2026 - Verekitug's phase II data support robust efficacy and safety, with phase III trials set to launch soon.UPB
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Verekitug shows robust efficacy and safety, with pivotal asthma data expected in 2026.UPB
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026 - Verekitug delivers robust efficacy and safety with extended dosing, targeting major respiratory markets.UPB
Corporate presentation12 Jan 2026